文献速递骨质疏松与代谢性骨病

绝经激素治疗在绝经后骨质疏松症管理中是否有作用?

Is there a role for menopausal hormone therapy in the management of postmenopausal osteoporosis?
PubMed 文献 · Osteoporos Int · 2020-07-08

本文通过叙述性综述评估绝经激素治疗(MHT)用于维持骨骼健康和预防近期绝经女性未来骨折的证据与指导。当前文献提示MHT在未筛选低骨密度患者中具有稳健的抗骨折疗效,但停药后骨骼获益持续的证据有限。总体获益-风险特征支持对近期(<10年)绝经、有绝经症状且年龄小于60岁、基线不良事件风险低的女性使用MHT。

要点

  • MHT在未筛选低骨密度患者中显示稳健抗骨折疗效,与是否联用孕激素无关。
  • 停药后骨骼获益持续的证据有限。
  • 获益-风险特征支持近期(<10年)绝经、有绝经症状、年龄<60岁且基线不良事件风险低的女性使用MHT。

核心结论

  • 总体获益-风险特征支持对近期(<10年)绝经、有绝经症状且年龄小于60岁、基线不良事件风险低的女性进行MHT治疗。
  • MHT应被视为维持女性骨骼健康的一种选择,特别是在治疗绝经症状的背景下作为额外获益,在绝经时或之后不久开始,并进行个体化获益-风险评价。

研究设计与样本

  • 本文为叙述性综述,评估使用MHT管理绝经后骨质疏松症的获益与风险。

主要发现

  • 当前文献提示MHT在未筛选低骨密度患者中具有稳健的抗骨折疗效,无论是否联用孕激素。
  • 停药后骨骼获益持续的证据有限。
  • 副作用包括心血管事件、血栓栓塞性疾病、卒中和乳腺癌。
  • 获益-风险特征因使用联合或不联合孕激素的雌激素、雌激素/孕激素类型、剂量和给药途径而异,其中心血管事件还因MHT使用时机而异。

关键数值与推荐

  • 总体获益-风险特征支持对近期(<10年)绝经、有绝经症状且年龄小于60岁、基线不良事件风险低的女性进行MHT治疗。
  • MHT应被视为维持女性骨骼健康的一种选择,特别是在治疗绝经症状的背景下作为额外获益,在绝经时或之后不久开始,并进行个体化获益-风险评价。

临床怎么用

  • MHT应被视为维持女性骨骼健康的一种选择,特别是在治疗绝经症状的背景下作为额外获益,在绝经时或之后不久开始,并进行个体化获益-风险评价。

局限性

  • 停药后骨骼获益持续的证据有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We provide an evidence base and guidance for the use of menopausal hormone therapy (MHT) for the maintenance of skeletal health and prevention of future fractures in recently menopausal women. Despite controversy over associated side effects, which has limited its use in recent decades, the potential role for MHT soon after menopause in the management of postmenopausal osteoporosis is increasingly recognized. We present a narrative review of the benefits versus risks of using MHT in the management of postmenopausal osteoporosis. Current literature suggests robust anti-fracture efficacy of MHT in patients unselected for low BMD, regardless of concomitant use with progestogens, but with limited evidence of persisting skeletal benefits following cessation of therapy. Side effects include cardiovascular events, thromboembolic disease, stroke and breast cancer, but the benefit-risk profile differs according to the use of opposed versus unopposed oestrogens, type of oestrogen/progestogen, dose and route of delivery and, for cardiovascular events, timing of MHT use. Overall, the benefit-risk profile supports MHT treatment in women who have recently (< 10 years) become menopausal, who have menopausal symptoms and who are less than 60 years old, with a low baseline risk for adverse events. MHT should be considered as an option for the maintenance of skeletal health in women, specifically as an additional benefit in the context of treatment of menopausal symptoms, when commenced at the menopause, or shortly thereafter, in the context of a personalized benefit-risk evaluation.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Rozenberg S, Al-Daghri N, Aubertin-Leheudre M, et al. Is there a role for menopausal hormone therapy in the management of postmenopausal osteoporosis? Osteoporos Int. 2020. PMID: 32642851. doi:10.1007/s00198-020-05497-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。